Morgan Stanley Vincerx Pharma, Inc. Transaction History
Morgan Stanley
- $1.35 Trillion
- Q3 2024
A detailed history of Morgan Stanley transactions in Vincerx Pharma, Inc. stock. As of the latest transaction made, Morgan Stanley holds 1,750 shares of VINC stock, worth $262. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,750
Previous 1,750
-0.0%
Holding current value
$262
Previous $1,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding VINC
# of Institutions
28Shares Held
11MCall Options Held
0Put Options Held
0-
Armistice Capital, LLC New York, NY2.7MShares$405,6000.03% of portfolio
-
Prosight Management, LP Dallas, TX2.21MShares$330,9750.43% of portfolio
-
Sage Rhino Capital LLC1.7MShares$255,5110.28% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD892KShares$133,7570.02% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct674KShares$101,1280.0% of portfolio
About Vincerx Pharma, Inc.
- Ticker VINC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 21,189,800
- Market Cap $3.18M
- Description
- Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candid...